Form 4: Invivyd CFO Granted 625,000 Stock Options

Invivyd, Inc.'s Chief Financial Officer, William E. Duke, was granted 625,000 stock options with an exercise price of $1.85, vesting over three years.

Summary

• William E. Duke, Chief Financial Officer of Invivyd, Inc., was granted 625,000 stock options.
• The options have an exercise price of $1.85 per share.
• The grant date for these options was January 29, 2026.
• The options vest over a three-year period, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date.
• Vesting is contingent upon Mr. Duke's continuous service with the company.
• The options expire on January 28, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management incentives with long-term shareholder value, which is generally favorable for corporate governance and performance.

Positives

• The grant of 625,000 stock options to the CFO aligns management's incentives with long-term shareholder value creation.
• A vesting schedule over three years encourages executive retention and sustained performance.

Risks

• The value of the stock options is dependent on the future performance of Invivyd, Inc.'s common stock exceeding the $1.85 exercise price.
• If the company's stock price does not appreciate above the exercise price, the options may expire worthless.

Future Outlook

The vesting schedule of the stock options over a three-year period implies an expectation of continued service from the Chief Financial Officer and a long-term commitment to the company's performance.

Industry Context

StockSavvy.ai notes that equity grants, particularly stock options with multi-year vesting schedules, are a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key executives. This aligns the interests of management with long-term shareholder value, a critical factor in an industry characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• Executive equity compensation, including stock options, is a standard practice across the biotech industry, comparable to companies like Moderna (MRNA) or BioNTech (BNTX) which frequently use such incentives for their leadership teams.
• A three-year vesting period is typical for executive stock option grants, promoting long-term commitment, similar to structures seen at companies like Gilead Sciences (GILD) or Amgen (AMGN).

Stakeholder Impact

• Shareholders: Potential positive impact if the options incentivize the CFO to drive stock price appreciation above the exercise price. Dilution risk if options are exercised in the future, though this is standard for equity compensation.
• Employees: No direct impact mentioned for general employees, but it reinforces the company's compensation strategy for key executives.

Next Steps

• The stock options will begin vesting in monthly installments starting one month after January 29, 2026.
• William E. Duke must maintain continuous service with Invivyd, Inc. for the options to continue vesting.

Key Dates

Recommendation

This Form 4 filing details a routine executive stock option grant, which is a standard component of compensation packages designed to align management incentives with long-term shareholder value. While positive for governance and retention, it does not present new information that would fundamentally alter the investment thesis for Invivyd, Inc. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial news.

Keywords

Invivyd, IVVD, Stock Options, Executive Compensation, Form 4, William E. Duke, CFO, Equity Grant, Beneficial Ownership